Overview

Phase 2 Study of Yimitasvir Phosphate Capsules

Status:
Completed

Trial end date:
2018-09-26

Target enrollment:

Participant gender:

Summary

The safety, tolerability and antiviral activity of DAG181/SOF in treatment-naive and treatment-experienced patients with chronic hepatitis C virus (HCV) genotype 1 infection

Phase:

Phase 2

Details

Lead Sponsor:

Sunshine Lake Pharma Co., Ltd.

Treatments:

Sofosbuvir
Yimitasvir